Tests give Fluad the all clear, says Italian agency
This article was originally published in Scrip
Executive Summary
Results of initial tests carried out on the two batches of Novartis' flu vaccine Fluad that were suspended in Italy on 27 November as a result of reports of serious adverse events, including deaths, are "completely negative" and show there is nothing wrong with the quality of the products, says the regulatory agency AIFA.
You may also be interested in...
Industry & Regulators To Align Advice on COVID-19 Vaccine Updates
A multi-stakeholder workshop looked at the data needed to support updates to vaccine composition and the time required by manufacturers to update their vaccines, change their manufacturing processes and prepare approval applications.
Denmark Planning To Impose Drug Stockpiling Obligations From July
A new bill is intended to address the increase in medicine supply problems in Denmark in recent years.
National Drug Stockpiles Create ‘False Sense Of Security’
The generics and biosimilars industry body Medicines for Europe says disparate national stockpiling requirements are not a solution to shortages and can bring “significant risks” for the supply chain and access to medicines.